Immuto Scientific Revenue and Competitors
Estimated Revenue & Valuation
- Immuto Scientific's estimated annual revenue is currently $3.3M per year.
- Immuto Scientific's estimated revenue per employee is $155,000
Employee Data
- Immuto Scientific has 21 Employees.
- Immuto Scientific grew their employee count by 24% last year.
Immuto Scientific's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-founder and CEO | Reveal Email/Phone |
2 | Co-Founder, Chief Technology Officer | Reveal Email/Phone |
3 | Co-Founder, Chief Technology Officer | Reveal Email/Phone |
4 | Chief Scientific Officer | Reveal Email/Phone |
5 | Head Commercial | Reveal Email/Phone |
6 | Scientific Director | Reveal Email/Phone |
7 | Scientist | Reveal Email/Phone |
8 | Scientist | Reveal Email/Phone |
Immuto Scientific Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $3.4M | 22 | 22% | N/A | N/A |
#2 | $2.3M | 15 | 36% | N/A | N/A |
#3 | $0.8M | 5 | -29% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $45.5M | N/A |
#6 | $1.6M | 10 | 11% | N/A | N/A |
#7 | $2M | 13 | 30% | N/A | N/A |
#8 | $1.4M | 9 | 29% | N/A | N/A |
#9 | $10.5M | 68 | -22% | N/A | N/A |
#10 | $0.3M | 2 | -50% | N/A | N/A |
What Is Immuto Scientific?
Immuto Scientific is a CRO specializing in protein characterization services serving the pharmaceutical industry. We utilize our patented technology to provide fast, high-resolution structural characterization of therapeutic proteins and antibodies in their native form to accelerate the lead validation process of drug development
keywords:N/AN/A
Total Funding
21
Number of Employees
$3.3M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.3M | 21 | 40% | N/A |
#2 | $4.8M | 21 | -9% | N/A |
#3 | $2.1M | 21 | 31% | N/A |
#4 | $3.7M | 21 | 62% | $9M |
#5 | $4.8M | 21 | -16% | N/A |